Get the Stockscreener App
36.80
0.86%
-0.32
Royalty Pharma Plc stock is traded at $36.80, with a volume of 2.16M.
It is down -0.86% in the last 24 hours and up +2.14% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$37.12
Open:
$37.09
24h Volume:
2.16M
Relative Volume:
0.56
Market Cap:
$15.51B
Revenue:
$2.26B
Net Income/Loss:
$1.09B
P/E Ratio:
15.71
EPS:
2.3431
Net Cash Flow:
$2.70B
1W Performance:
+0.57%
1M Performance:
+2.14%
6M Performance:
+16.53%
1Y Performance:
+30.64%
1-Day Range:
$36.71
$37.55
1-Week Range:
$36.29
$37.56
52-Week Range:
$24.05
$37.56
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
36.80 | 15.64B | 2.26B | 1.09B | 2.70B | 2.3431 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Ridgewood Investments LLC Trims Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
What are Royalty Pharma plc company’s key revenue driversFinancial News Planner For Consistent Profits - jammulinksnews.com
Royalty Pharma (RPRX) to Release Quarterly Earnings on Wednesday - MarketBeat
Y Intercept Hong Kong Ltd Acquires New Shares in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
What catalysts could drive Royalty Pharma plc stock higher in 2025Daily Trading Insights With High Returns - jammulinksnews.com
Allianz Asset Management GmbH Has $6.03 Million Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Signal strength of Royalty Pharma plc stock in tech scannersStable Entry High Return Opportunities in Focus - metal.it
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Pacific Capital Partners Ltd Takes Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Envestnet Asset Management Inc. Boosts Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Fibonacci Support Holding Strong in Royalty Pharma plcCommunity Verified Stock Suggestions Drive Volume - metal.it
Royalty Pharma plc stock volume spike explainedScalable Portfolio Growth Suggestions Released - metal.it
Published on: 2025-07-29 22:21:39 - metal.it
Royalty Pharma PLC (NASDAQ:RPRX) Shares Sold by Mediolanum International Funds Ltd - MarketBeat
Baillie Gifford & Co. Decreases Stake in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Machine Learning Models Forecast Royalty Pharma plc UptickConsistent Income Focused Trade List Analyzed - metal.it
Can Royalty Pharma plc Regain Momentum After BreakdownCommunity Shared Smart Money Signals Show Movement - metal.it
Bollinger Bands Expand on Royalty Pharma plc — Volatility AheadWeekly Chart Analysis With Entry Advice Provided - metal.it
Royalty Pharma stock hits 52-week high at 36.89 USD - Investing.com Australia
Why is Royalty Pharma plc stock attracting strong analyst attentionExceptional stock performance - jammulinksnews.com
Is it the right time to buy Royalty Pharma plc stockSuperior portfolio returns - jammulinksnews.com
What makes Royalty Pharma plc stock price move sharplyInvest confidently with real-time updates - jammulinksnews.com
Cwm LLC Increases Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
What is Royalty Pharma plc company’s growth strategyUnmatched profit growth - jammulinksnews.com
How does Royalty Pharma plc compare to its industry peersCapitalize on strong market momentum - jammulinksnews.com
Is Royalty Pharma plc stock overvalued or undervaluedUnlock powerful trading signals and alerts - jammulinksnews.com
Published on: 2025-07-28 08:51:02 - jammulinksnews.com
What markets is GCLWW expanding into Is Royalty Pharma plc stock a good long term investment optionGet daily updates on promising stocks - jammulinksnews.com
What are the latest earnings results for Royalty Pharma plcMaximize your portfolio’s earning potential - jammulinksnews.com
When is Royalty Pharma plc stock expected to show significant growthDynamic profit opportunities - jammulinksnews.com
Vestor Capital LLC Takes $12.60 Million Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Sets New 12-Month HighHere's What Happened - MarketBeat
Royalty Pharma: A High-Margin, Earnings-Driven Opportunity in the Biopharma Royalty Space - AInvest
What analysts say about Royalty Pharma plc stockFree Wealth Planning Blueprint - PrintWeekIndia
Royalty Pharma plc Stock Analysis and ForecastSuperior portfolio returns - PrintWeekIndia
Is Royalty Pharma plc a good long term investmentDouble-digit growth - Autocar Professional
Royalty Pharma (NASDAQ:RPRX) Given New $42.00 Price Target at Citigroup - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Holdings Lifted by Los Angeles Capital Management LLC - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Shares Sold by New York State Common Retirement Fund - MarketBeat
Royalty Pharma Plc's (NASDAQ:RPRX) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? - 富途牛牛
Winners And Losers Of Q1: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):